The work, led by Roswell Park’s Katerina Gurova, PhD, and Sethera CEO Karsten Eastman, PhD, could open a path toward targeted options for patients with aggressive tumors that have limited treatment choices
August 10, 2026
The work, led by Roswell Park’s Katerina Gurova, PhD, and Sethera CEO Karsten Eastman, PhD, could open a path toward targeted options for patients with aggressive tumors that have limited treatment choices